• 1
    Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet. 1980; 1: 514.
  • 2
    Present DH, Korelitz BI, Wisch N, et al. Treatment of Crohn's disease with 6-mercaptopurine: a long-term, randomized, double-blind study. N Engl J Med. 1980; 302: 981987.
  • 3
    Myren J, Bouchier IA, Watkinson G, et al. The O.M.G.E. Multinational Inflammatory Bowel Disease Survey 1976-1982: a further report on 2,657 cases. Scand J Gastroenterol Suppl. 1984; 95: 127.
  • 4
    Wright JP, Marks IN, Parfitt A. Asimple clinical index of Crohn's disease activity: the Cape Town index. S Afr Med J. 1985; 68: 502503.
  • 5
    van Hees PA, van Elteren PH, van Lier HJ, et al. An index of inflammatory activity in patients with Crohn's disease. Gut. 1980; 21: 279286.
  • 6
    Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn's disease activity index: National Cooperative Crohn's Disease Study. Gastroenterology. 1976; 70: 439444.
  • 7
    Best WR, Becktel JM, Singleton JW. Rederived values of the eight coefficients of the Crohn's Disease Activity Index (CDAI). Gastroenterology. 1979; 77: 843846.
  • 8
    Sandler RS, Jordan MC, Kupper LL. Development of a Crohn's index for survey research. J Clin Epidemiol. 1988; 41: 451458.
  • 9
    de Dombal FT, Softley A. IOIBD report no 1: Observer variation in calculating indices of severity and activity in Crohn's disease: International Organisation for the Study of Inflammatory Bowel Disease. Gut. 1987;28: 474481.
  • 10
    Irvine EJ, Feagan B, Rochon J, et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease: Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology. 1994; 106: 287296.
  • 11
    Acciuffi S, Ghosh S, Ferguson A. Strengths and limitations of the Crohn's disease activity index, revealed by an objective gut lavage test of gastrointestinal protein loss. Aliment Pharmacol Ther. 1996; 10: 321326.
  • 12
    Papi C, Ciaco A, Bianchi M, et al. Correlation of various Crohn's disease activity indexes in subgroups of patients with primarily inflammatory or fibrostenosing clinical characteristics. J Clin Gastroenterol. 1996; 23: 4043.
  • 13
    Irvine EJ. Usual therapy improves perianal Crohn's disease as measured by a new disease activity index: McMaster IBD Study Group. J Clin Gastroenterol. 1995; 20: 2732.
  • 14
    Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004; 350: 876885.
  • 15
    Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002; 359: 15411549.
  • 16
    Sandborn WJ, Feagan B, Radford-Smith G, et al. A randomized, placebo-controlled trial of CDP571, a humanized monoclonal antibody to TNF-α, in patients with moderate to severe Crohn's disease. Gastroenterology. 2003; 124: A61.
  • 17
    Schreiber S, Rutgeerts P, Fedorak RN, et al. CDP870, a humanized anti-TNF antibody fragment, induces clinical response with remission in patients with active Crohn's disease. Gastroenterology. 2003; 124: A61.
  • 18
    Andre C, Descos L, Landais P, et al. Laboratory supplementation of Crohn's disease activity index. Lancet. 1980; 2: 594595.
  • 19
    Andre C, Descos L, Landais P, et al. Assessment of appropriate laboratory measurements to supplement the Crohn's disease activity index. Gut. 1981; 22: 571574.
  • 20
    Summers RW, Switz DM, Sessions JT Jr, et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology. 1979; 77: 847869.